Open AccessMethylation of TMEM176A, a key ERK signaling regulator, is a novel synthetic lethality marker of ATM inhibitors in human lung cancer
Author(s) -
Hongxia Li,
Weili Yang,
Meiying Zhang,
Tao He,
Fuyou Zhou,
James G. Herman,
Liming Hu,
Mingzhou Guo
Publication year - 2021
Publication title -
epigenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.265
H-Index - 60
eISSN - 1750-1911
pISSN - 1750-192X
DOI - 10.2217/epi-2021-0217
Subject(s) - methylation , lung cancer , cancer research , biology , cancer , dna methylation , cell growth , mapk/erk pathway , synthetic lethality , apoptosis , cancer cell , signal transduction , microbiology and biotechnology , gene expression , gene , pathology , dna repair , medicine , genetics
Aim: The role of TMEM176A methylation in lung cancer and its therapeutic application remains unclear. Materials and methods: Nine lung cancer cell lines and 123 cases of cancer tissue samples were employed. Results: TMEM176A was methylated in 53.66% of primary lung cancer. Restoration of TMEM176A expression induced cell apoptosis and G2/M phase arrest, and inhibited colony formation, cell proliferation, migration and invasion. TMEM176A suppressed H1299 cell xenograft growth in mice. Methylation of TMEM176A activated ERK signaling and sensitized H1299 and H23 cells to AZD0156, an ATM inhibitor. Conclusion: The expression of TMEM176A is regulated by promoter region methylation. Methylation of TMEM176A is a potential lung cancer diagnostic marker and a novel synthetic lethal therapeutic marker for AZD0156.